Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

Peking Union Medical College Hospital (PUMCH)., Beijing, Beijing Municipality